Difference between revisions of "Sotorasib (Lumakras)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sotorasib NCI Drug Dictionary]: An orally available agent that targets the s...") |
m |
||
| Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sotorasib NCI Drug Dictionary]: An orally available agent that targets the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets the KRAS p.G12C mutant, at either the DNA, RNA or protein level, and prevents, through an as of yet not elucidated manner, expression of and/or tumor cell signaling through the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sotorasib NCI Drug Dictionary]: An orally available agent that targets the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets the KRAS p.G12C mutant, at either the DNA, RNA or protein level, and prevents, through an as of yet not elucidated manner, expression of and/or tumor cell signaling through the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. | ||
| − | == | + | ==Diseases for which it is used== |
| − | * | + | *[[Non-small cell lung cancer, KRAS-mutated]] |
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *5/28/2021: Accelerated approval for adult patients with KRAS G12C‑mutated locally advanced or metastatic [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]], as determined by an FDA‑approved test, who have received at least one prior systemic therapy. ''(Based on CodeBreaK100)'' | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:'' AMG 510 | ||
| + | *'''Brand name:''' Lumakras | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:KRAS inhibitors]] | [[Category:KRAS inhibitors]] | ||
| + | [[Category:Mutation-specific medications]] | ||
| + | |||
| + | [[Category:Non-small cell lung cancer medications]] | ||
| − | [[Category: | + | [[Category:FDA approved in 2021]] |
Revision as of 15:10, 1 June 2021
Mechanism of action
From the NCI Drug Dictionary: An orally available agent that targets the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets the KRAS p.G12C mutant, at either the DNA, RNA or protein level, and prevents, through an as of yet not elucidated manner, expression of and/or tumor cell signaling through the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells.
Diseases for which it is used
History of changes in FDA indication
- 5/28/2021: Accelerated approval for adult patients with KRAS G12C‑mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA‑approved test, who have received at least one prior systemic therapy. (Based on CodeBreaK100)
Also known as
- 'Code name: AMG 510
- Brand name: Lumakras